Drugs / Golcadomide
Golcadomide
also known as
CC-99282 · BMS-986369 · BMS-986369-05 · BMS-986369-05, CC-99282 · CC-99282 HYDROCHLORIDE · CC1007548 · Golcadomida · Golcadomide (GOLCA; CC-99282) · +1 more
Trials 26 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07608731 | Jun 2026 → Apr 2029 expected | diffuse large B-cell lymphoma of the central nervous system, large B-cell lymphoma | Allison Winter | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06535399 | Aug 2024 → Nov 2025 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06363630 | Apr → Aug 2024 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06209619 | Jan 2024 → Dec 2026 expected | follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Nathan Denlinger | Recruiting | No outcome recorded |
| Phase 1 | NCT05169515 | Oct 2022 → Sep 2029 expected | B-cell non-Hodgkin lymphoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT05567510 | Oct → Dec 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05350800 | Sep 2022 → May 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04884035 | Sep 2021 → Dec 2028 expected | B-cell non-Hodgkin lymphoma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04434196 | Dec 2020 → May 2024 | non-Hodgkin lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT07578077 | Dec 2026 → Apr 2030 expected | mantle cell lymphoma | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07269639 | Jan 2026 → Dec 2027 expected | large B-cell lymphoma | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07018752 | Aug 2025 → Apr 2028 expected | peripheral T-cell lymphoma, not otherwise specified | The Lymphoma Academic Research Organisation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06767956 | Jun 2025 → Apr 2027 | non-Hodgkin lymphoma | University of Pittsburgh | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06090539 | Dec 2023 → Oct 2027 expected | non-Hodgkin lymphoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06035497 | Nov 2023 → Jan 2027 expected | T-cell non-Hodgkin lymphoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03930953 | May 2019 → Apr 2027 expected | non-Hodgkin lymphoma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03310619 | Dec 2017 → Feb 2023 | diffuse large B-cell lymphoma, follicular lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06835530 | Apr 2025 → Apr 2030 expected | diffuse large B-cell lymphoma | Fondazione Italiana Linfomi - ETS | Recruiting | No outcome recorded |
| Phase 2 | NCT06834373 | Apr 2025 → Mar 2027 expected | ALK-positive large B-cell lymphoma, Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma activated B-cell type +8 | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06425302 | Aug 2024 → Nov 2026 expected | follicular lymphoma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06271057 | Jun 2024 → Mar 2027 expected | monofixation syndrome, primary mediastinal large B-cell lymphoma, relapsed/refractory diffuse large B-cell lymphoma | The Lymphoma Academic Research Organisation | Recruiting | No outcome recorded |
| Phase 2 | NCT06108232 | Mar 2024 → Dec 2027 expected | follicular lymphoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05788081 | Aug 2023 → Jan 2027 expected | follicular lymphoma | Olivia Newton-John Cancer Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05283720 | Jun 2022 → Nov 2032 expected | non-Hodgkin lymphoma | Genmab | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06911502 | Jul 2025 → Apr 2028 expected | follicular lymphoma | Celgene Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT06356129 | Jun 2024 → Aug 2027 expected | large B-cell lymphoma | Celgene Corporation | Active not recruiting | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Golcadomide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06835530 ↗ |
| Known as | BMS-986369 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06035497 ↗ |
| Known as | BMS-986369-05 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Known as | BMS-986369-05, CC-99282 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Known as | CC-99282 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03310619 ↗ |
| Known as | CC-99282 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Known as | CC1007548 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Known as | Golcadomida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Known as | Golcadomide (GOLCA; CC-99282) | “Golcadomide (GOLCA; CC-99282)” NCT06767956 ↗ |
| Known as | GOLCADOMIDE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Modality | Other / unclassified | “golcadomide (CELMoD)” NCT06271057 ↗ |
| Route | Oral | “Orally Available Small Molecule, CC-99282” NCT03930953 ↗ |